New tool aims to simplify vasectomy procedures
NCT ID NCT06891729
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new device called the Delivery Lumen Access Device (DLAD) in 24 healthy men who were already planning to have a vasectomy. The device is designed to help doctors access the vas deferens more easily. Researchers checked for side effects and how well the device worked during the procedure.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Delivery Lumen Access Device (DLAD)
- What this could lead to
- If it works, this device could make vasectomy procedures easier and safer for patients.
- What could go wrong
- This is a small, early-stage study with only 24 participants, so results may not apply to everyone. The device might still have unexpected risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
24 people
The number who actually took part.
- Started
-
Mar 2025
- Finished
-
Jun 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Male participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male subject who has already planned to undergo a vasectomy. 2. Male subject who has voluntarily signed and dated the Institutional Review Board (IRB)/Ethics Committee (EC) approved informed consent form (ICF) for this study before initiation of any screening or study-specific procedures. 3. 18 to 65 years of age at the time of consent. 4. Good health for undergoing a vasectomy procedure as confirmed by medical history and physical examination. 5. In the opinion of the Investigator, the subject is suitable to undergo a vasectomy procedure as a form of long-term contraception. Exclusion Criteria: 1. On exam, has any of the following: one or both vasa not present, abnormal scrotum, large varicocele, hydrocele, filariasis or elephantiasis of scrotum, or an intrascrotal mass that would make the subject not suitable for the study. 2. Prior testicular surgery, testicular injury, or prior vasectomy with vasovasostomy (vasectomy reversal). 3. Has local genital infections such as balanitis, scrotal skin infection, epididymitis, or orchitis, or tender (inflamed) tip of the penis, but may be enrolled after resolution of an acute infection. 4. History of prostatitis or benign prostatic hypertrophy requiring treatment. 5. Has known current coagulopathy or other bleeding disorders. 6. Known allergy to DLAD materials including nickel, stainless steel and silicone. 7. Has cystic fibrosis. 8. Has history of inguinal hernia repair. 9. The subject belongs to a vulnerable population. Vulnerable subject populations are defined as individuals who are incarcerated, handicapped, have cognitive challenges, mental disability, persons in nursing homes, children, impoverished persons, homeless persons, economically or educationally disadvantaged persons, nomads, refugees and those permanently incapable of giving informed consent. Vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the sponsor, members of the armed forces and persons kept in detention. 10. Currently participating in another study involving an investigational device or drug within the last 30 days prior to the first screening. 11. Any site staff member with delegated study responsibilities or a family member of a site staff member with delegated study responsibilities. 12. In the opinion of the Investigator, there are issues or concerns that may compromise the safety of the subject or confound the reliability of compliance and information acquired in this study. 13. Has any condition that, in the opinion of the Investigator, would interfere with evaluation of DLAD product performance or interpretation of patient safety or study results.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy male adults participants are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Epworth HealthCare
Melbourne, Victoria, 3002, Australia
-
VasectoPro
Québec, Quebec/Canada, G1H7B5, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.